| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | H1 | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $285.21M | Series D-1 | 12/19/2024 | $88.46M | $404.74M | $9.00 | Undisclosed Investors | ||||
 | Phil | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $119.43M | Series D | 7/3/2021 | $61.34M | $321.12M | $4.06 | Warburg Pincus | ||||
 | SetPoint Medical | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $303.01M | Series D | 8/11/2025 | $115M | $471.62M | $1.51 | Elevage Medical Technologies, Ally Bridge Group, Northwell Health, SPRIG Equity, Norwest Venture Partners, New Enterprise Associates, Viking Global Investors, Action Potential Venture Capital, Abbott, Boston Scientific, Euclidean Capital, Richard King Mellon Foundation, Morgenthaler Ventures, ShangBay Capital, Ascendum Capital, Catalio Capital Management, Gilmartin Capital, Midas Capital | ||||
 | Umoja Biopharma | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $373.84M | Series C | 1/14/2025 | $100M | $422.45M | $3.95 | Double Point Ventures, DCVC Bio, ARK Invest, Cormorant Asset Management, MPM Capital, Qiming Venture Partners USA, RTW Investments, Alexandria Venture Investments, SoftBank, CaaS Capital, Emerson Collective, K2 HealthVentures, Myeloma Investment Fund, University of Minnesota | ||||
 | A2 Biotherapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $287.63M | Series C | 1/9/2025 | $80M | $274.56M | $0.74 | The Column Group, Samsara BioCapital | ||||
 | Aerin Medical | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $172.7M | Series G | 1/13/2025 | $32.82M | $342.42M | $1.17 | KCK MedTech, Questa Capital, OrbiMed, Ally Bridge Group, Ares Capital | ||||
 | Atavistik | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $260M | Series B-1 | 3/5/2026 | $40M | $422.55M | $1.20 | RA Capital Management | ||||
 | Baylor Genetics | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $152M | Series B | 7/1/2026 | $50M | $443.35M | $19.25 | Undisclosed Investors | ||||
 | Harbor Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $384.26M | Series A-4-4 | 2/20/2026 | $45M | $436.68M | $0.71 | Undisclosed Investors | ||||
 | KSQ Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $417.49M | Series D-1 | 10/24/2025 | $160.03M | $486.98M | $2.65 | Undisclosed Investors | ||||
 | LightForce | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $150.18M | Series D-X | 8/2/2023 | $40M | $403.11M | $18.01 | Ally Bridge Group, Transformation Capital, CareCapital, Omega Venture Partners, Matter Venture Partners, American Association of Orthodontics, Kleiner Perkins, Tyche Partners, Matrix Partners | ||||
 | Relievant Medsystems | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $247.66M | Series G | 3/17/2023 | $50M | $361.21M | $0.11 | Undisclosed Investors | ||||
 | restor3d | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $155.97M | Series B-1 | 8/22/2025 | $65M | $265.79M | $2.60 | Partners Group | ||||
 | Affinia Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $219.17M | Series C | 10/7/2025 | $40M | $156.61M | $1.62 | New Enterprise Associates, Eli Lilly, Alexandria Venture Investments, Atlas Venture, Avidity Partners, F-Prime Capital, GV, Mass General Brigham Ventures, Perceptive Advisors | ||||
 | AIRNA | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $245.25M | Series B | 4/1/2025 | $155M | $330.71M | $0.93 | Venrock, Forbion, RTW Investments, Nextech Invest, ARCH Venture Partners, ND Capital | ||||
 | AiTA | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $25.63M | Series C | 1/14/2025 | $10M | $317.19M | $5.05 | Undisclosed Investors | ||||
 | Be Biopharma | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $274.72M | Series C | 1/15/2025 | $92.62M | $154.23M | $2.90 | ARCH Venture Partners, Atlas Venture, RA Capital Management, Alta Partners, Longwood Fund, Bristol Myers Squibb, Takeda Ventures, Nextech | ||||
 | Clear Labs | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $157.08M | Series D | 1/13/2025 | $30M | $395.17M | $2.80 | Counterpoint Global, Felicis, GV, HBM Genomics, Khosla Ventures, Menlo Ventures, Nimble Ventures, Redmile Group, Wing Venture Capital, T. Rowe Price Associates | ||||
 | DeepScribe | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $59.19M | Series B | 1/3/2024 | $24M | $134.68M | $3.45 | Undisclosed Investors | ||||
 | Eligible | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $4.36M | Series Seed | 1/13/2015 | $4.36M | $20.68M | $1.41 | Y Combinator, Deerfield Management, RTA Capital, MetaLab | ||||
 | Epic Sciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $606.66M | Series A-3 | 12/29/2023 | $20.9M | $94.14M | $3.00 | Undisclosed Investors | ||||
 | Flare Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $290.35M | Series C | 6/30/2026 | $85M | $188.49M | $0.37 | Third Rock Ventures, Nextech Invest, Pfizer, Boxer Capital, GordonMD Global Investments, Invus, Casdin Capital, Eli Lilly and Company, Novartis, Agent Capital, Eventide Asset Management | ||||
 | Foresight | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $144.31M | Series D | 1/30/2025 | $25M | $35.83M | $0.24 | Undisclosed Investors | ||||
 | GT Medical Technologies | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $219.98M | Series E | 6/9/2026 | $100M | $364.93M | $2.61 | Viking Global Investors, MVM Partners, Gilde Healthcare, Evidity Health Capital, MedTech Venture Partners, FemHealth Ventures | ||||